Lieber Institute & AWS: Brain Disorder Drug Discovery
Harnessing the power of AI, the Lieber Institute is revolutionizing brain disorder research with Amazon web Services (AWS). The institute leverages AWS’s cutting-edge generative AI and expansive computing services to develop GRAPE, a groundbreaking tool designed to discover more effective treatments for complex conditions like schizophrenia. This innovative approach accelerates data analysis and streamlines global collaboration, enhancing brain research speed and efficiency. The collaboration stores genomic data in the cloud,offering scientists unparalleled access to computing power and advanced AI. This strategy is poised to transform brain disorder treatment.News Directory 3 reports on the exciting developments. Discover what’s next in the quest for innovative treatments for brain disorders.
Lieber Institute Taps AI for Brain Disorder Research
The Lieber Institute for Brain Development (LIBD) is enhancing its technological infrastructure on Amazon Web Services (AWS) to advance its research into brain disorders. The institute will migrate its IT to fully utilize AWS generative AI and computing services.
As a recipient of the 2024 AWS IMAGINE Grant,the Lieber Institute plans to develop a new tool called GRAPE. This tool combines generative and predictive AI to discover more effective treatments for brain disorders, including schizophrenia. The institute seeks to improve brain disorder treatment through AI drug design.
Building on AWS allows the Lieber Institute to store its extensive collection of genomic data in the cloud. This provides scientists with access to meaningful computing power and advanced AI capabilities. Cloud storage also streamlines data sharing and collaboration among researchers worldwide, facilitating brain research.
The human genome contains billions of data points, and the human brain contains billions of cells.Analyzing this data requires cutting-edge tools. Lieber Institute scientists are working with AWS solution architects to develop custom AI applications.Thes applications make deep learning accessible to all scientists at the institute, regardless of their coding expertise.
Jeff Kratz, vice president of Nonprofit and Public Sector Industries at AWS, said AWS’s AI capabilities provide the speed, security, and scale needed to drive research innovation. This will radically change outcomes for people affected by brain health issues, Kratz added.
GRAPE, or Generative Reinforcement Alignment of Predicted Expression, represents a new frontier in generative AI for drug design. The AWS IMAGINE Grant supports this project with up to $200,000 in unrestricted funding and $100,000 in AWS Promotional Credits.
GRAPE addresses the limitations of existing drugs for conditions like schizophrenia. These drugs often target only a few of the many risk genes involved.The new AI tool will design novel molecular structures for potential drugs based on known gene expression patterns of these complex disorders. GRAPE uniquely combines generative AI to design new drugs with predictive AI to evaluate their effectiveness, aiming to treat the root cause of the disease.
Dr. Michael Nagle, a staff scientist at the institute, said powerful supercomputing resources and new techniques are needed to maximize the impact of AI.GRAPE represents an opportunity to maximize impact for as many patients or conditions as possible, Nagle added.
The collaboration is already yielding significant efficiency gains. Dr. Frank Piscotta, another staff scientist, uses a technique called “cell painting” to identify new drug targets. Analysis that once took almost a week can now be completed in about 30 minutes on AWS.
What’s next
The Lieber Institute plans to continue expanding its use of AWS services to further accelerate its research and develop new treatments for brain disorders. The institute aims to make GRAPE available to othre researchers in the future.